Hospira to Handle Fill-Finish Operations for Genzyme's Multiple Drugs - - BioPharm International

ADVERTISEMENT

Hospira to Handle Fill-Finish Operations for Genzyme's Multiple Drugs



Genzyme Corp (Cambridge, MA), which has been trying to resolve its manufacturing problems at its Allston Landing plant last June, has signed a new supply agreement with Hospira Inc (Lake Forest, Illinois) for fill-finish operations of seven products, according to a recent report by Reuters.

In May, Genzyme agreed to terms of a consent decree with the FDA, which requires the company to move its fill-finish operations out of the Allston Landing plant for Cerezyme, Fabrazyme, and Thyrogen, and Myozyme. Under the new agreement, Hospira will now also handle the fill-finish operations for Lumizyme, Thymoglobulin, Campath, and other products now being developed by Genzyme.

Under the terms of the consent decree Genzyme also will pay the government $175 million in profits from past sales of certain drugs.

Previous coverage:
Genzyme Expects $175 Million Fine

Genzyme to Exit Fill-Finish Operations at Allston Landing Plant

FDA Takes Enforcement Action Regarding Genzyme's Allston Plant

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here